Patents by Inventor Markus Huber-Lang

Markus Huber-Lang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210355178
    Abstract: The present invention relates to a multi-module polypeptide comprising (i) an Fc receptor binding module; (ii) a first complement control protein repeat (CCP) module; and (iii) a second CCP module binding to at least one host cell surface marker, to complement factor C3b, to complement factor C4b, to a degradation product of complement factor C3b, and/or to a degradation product of complement factor C4b; wherein said second CCP module is C-terminal of said Fc receptor binding module and of said first CCP module. The present invention also relates to a polynucleotide encoding said multi-module polypeptide, and to said multi-module polypeptide for use in medicine, in particular for use in treating and/or preventing inappropriate complement activation and/or a disease having inappropriate complement activation as a symptom.
    Type: Application
    Filed: June 21, 2019
    Publication date: November 18, 2021
    Inventors: Christoph Schmidt, Markus Huber-Lang
  • Patent number: 7455837
    Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of sepsis. The present invention also provides methods of providing a prognosis to a patient with sepsis. In particular, the present invention relates to compositions and methods for the detection of C5aR expression and the correlation of C5aR expression level with prognosis in sepsis.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: November 25, 2008
    Assignee: The Regents of the University of Michigan
    Inventors: Renfeng Guo, Niels C. Riedemann, Peter A. Ward, Markus Huber-Lang, J. Vidya Sarma
  • Publication number: 20060159684
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.
    Type: Application
    Filed: September 27, 2005
    Publication date: July 20, 2006
    Applicant: The Regents of The University Of Michigan
    Inventors: Peter Ward, Markus Huber-Lang, Vidya Sarma, Boris Czermak
  • Patent number: 6987166
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: January 17, 2006
    Assignee: The Regents of the Univeristy of Michigan
    Inventors: Peter A. Ward, Markus Huber-Lang, Vidya Sarma, Boris Czermak
  • Patent number: 6866845
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: March 15, 2005
    Assignee: The Regents of the University of Michigan
    Inventors: Peter A. Ward, Markus Huber-Lang, Vidya Sarma
  • Publication number: 20040166541
    Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of sepsis. The present invention also provides methods of providing a prognosis to a patient with sepsis. In particular, the present invention relates to compositions and methods for the detection of C5aR expression and the correlation of C5aR expression level with prognosis in sepsis.
    Type: Application
    Filed: November 5, 2003
    Publication date: August 26, 2004
    Applicant: The Regents of the University of Michigan
    Inventors: Renfeng Guo, Niels C. Riedemann, Peter A. Ward, Markus Huber-Lang, J. Vidya Sarma
  • Patent number: 6673346
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: January 6, 2004
    Assignee: The Regents of the University of Michigan
    Inventors: Peter A. Ward, Markus Huber-Lang, Vidya Sarma, Boris Czermak
  • Publication number: 20020165138
    Abstract: The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and treatment of sepsis in humans as well as other animals. The present invention also relates to methods of generating anti-C5a antibodies employing C-terminal truncated C5a peptides.
    Type: Application
    Filed: June 11, 2001
    Publication date: November 7, 2002
    Applicant: The Regents of The University of Michigan
    Inventors: Peter A. Ward, Markus Huber-Lang, Vidya Sarma, Boris Czermak